l General Information |
Product Name | Saracatinib |
General description | Saracatinib is a potent Src inhibitor |
Synonym | N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4 amine; AZD0530 |
Purity | ≥98.0%(HPLC) | CAS Number | 379231-04-6 |
Formula | C27H32ClN5O5 | Molecular Weight | 542.033 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25℃) | DMSO | ≥25mg/mL |
Ethanol | ≥25mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Saracatinib is an orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption. |
Application | 1. Antineoplastic Agents Substances that inhibit or prevent the proliferation of neoplasms. 2. Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. |
l Packaging & Storage |
Packaging | 5mg; 25mg; 100mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
